Scholarlink

<p>Owing to the rarity of radical cystectomy (RC) for non-muscle-invasive bladder cancer (NMIBC), information regarding oncological outcomes is limited. The aim was to conduct a comprehensive analysis of risk factors and survival outcomes following RC. This retrospective study included 435 patients who underwent RC for clinically diagnosed NMIBC at multiple institutions in Japan. The 5-year cancer-specific survival (CSS) rates were 97.4% for cTa, 93.3% for cTis, and 85.4% for cT1, respectively. Among 351 patients with cTa and cT1 disease, multivariable Cox proportional hazards analyses identified upstaging to ≥pT2 or pN+ disease as the most impactful risk factor associated with cancer-specific mortality (hazard ratio = 6.53; <i>p</i> &lt; 0.001). Neither neoadjuvant chemotherapy nor lymph node dissection (LND) exhibited a survival benefit in terms of CSS in this cohort; however, LND was occasionally indicative of pN+ disease, suggesting potential diagnostic value. The multivariable logistic regression analysis of preoperative variables identified tumour size (≥ 3&#xa0;cm) as the lone risk factor associated with upstaging (odds ratio = 1.90; <i>p</i> = 0.03). In the sensitivity analyses, tumour size ≥ 3&#xa0;cm still trended toward an increased upstaging risk, without a statistically significant association. Although the prediction of upstaging remains highly challenging, RC should not be delayed when clinically indicated, even for patients diagnosed with NMIBC, particularly in those with large tumours.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月5日

查看全文
  • Takeshi Sano,
  • Rikiya Taoka,
  • Jun Miki,
  • Ryoichi Saito,
  • Wataru Fukuokaya,
  • Yoshiyuki Matsui,
  • Shingo Hatakeyama,
  • Takashi Kawahara,
  • Ayumu Matsuda,
  • Taketo Kawai,
  • Minoru Kato,
  • Tomokazu Sazuka,
  • Fumihiko Urabe,
  • Soki Kashima,
  • Hirohito Naito,
  • Yoji Murakami,
  • Makito Miyake,
  • Kei Daizumoto,
  • Yuto Matsushita,
  • Takuji Hayashi,
  • Junichi Inokuchi,
  • Yusuke Sugino,
  • Kenichiro Shiga,
  • Noriya Yamaguchi,
  • Shingo Yamamoto,
  • Keiji Yasue,
  • Takashige Abe,
  • Shotaro Nakanishi,
  • Katsuyoshi Hashine,
  • Masato Fujii,
  • Kiyoaki Nishihara,
  • Hiroaki Matsumoto,
  • Shuichi Tatarano,
  • Koichiro Wada,
  • Sho Sekito,
  • Ryo Maruyama,
  • Naotaka Nishiyama,
  • Hiroyuki Nishiyama,
  • Hiroshi Kitamura,
  • Takashi Kobayashi

摘要

Owing to the rarity of radical cystectomy (RC) for non-muscle-invasive bladder cancer (NMIBC), information regarding oncological outcomes is limited. The aim was to conduct a comprehensive analysis of risk factors and survival outcomes following RC. This retrospective study included 435 patients who underwent RC for clinically diagnosed NMIBC at multiple institutions in Japan. The 5-year cancer-specific survival (CSS) rates were 97.4% for cTa, 93.3% for cTis, and 85.4% for cT1, respectively. Among 351 patients with cTa and cT1 disease, multivariable Cox proportional hazards analyses identified upstaging to ≥pT2 or pN+ disease as the most impactful risk factor associated with cancer-specific mortality (hazard ratio = 6.53; p < 0.001). Neither neoadjuvant chemotherapy nor lymph node dissection (LND) exhibited a survival benefit in terms of CSS in this cohort; however, LND was occasionally indicative of pN+ disease, suggesting potential diagnostic value. The multivariable logistic regression analysis of preoperative variables identified tumour size (≥ 3 cm) as the lone risk factor associated with upstaging (odds ratio = 1.90; p = 0.03). In the sensitivity analyses, tumour size ≥ 3 cm still trended toward an increased upstaging risk, without a statistically significant association. Although the prediction of upstaging remains highly challenging, RC should not be delayed when clinically indicated, even for patients diagnosed with NMIBC, particularly in those with large tumours.